J Neurol Res
Journal of Neurology Research, ISSN 1923-2845 print, 1923-2853 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Neurol Res and Elmer Press Inc
Journal website http://www.neurores.org

Case Report

Volume 10, Number 1, February 2020, pages 17-19


Dramatic Recovery of a Patient With Wernicke Encephalopathy Presenting With the Lesion of the Corpus Callosum

Halil Onder

Neurology Clinic, Yozgat City Hospital, Yozgat, Turkey

Manuscript submitted December 2, 2019, accepted December 16, 2019
Short title: WE Presenting With a Callosal Lesion
doi: https://doi.org/10.14740/jnr559

Abstract▴Top 

In this report, I present a rare patient of Wernicke encephalopathy (WE) with a callosal lesion on magnetic resonance imaging at whom a dramatic clinical recovery was achieved by parenteral thiamine therapy. Based on the presentation of this patient, first, I suggest that the awareness of WE among clinicians should be further increased. Second, I re-emphasize the importance of initiation of parenteral thiamine treatments in clinical suspicion of WE which may provide dramatic responses even in patients with atypical lesion sites as in our patient. Future reports including outcomes of a larger number of cases with distinct neuroimaging signs may provide a better understanding of the real clinical burden of the disease as well as unknown aspects of WE.

Keywords: Wernicke encephalopathy; Corpus callosum; Parenteral thiamine; Recovery

Introduction▴Top 

Wernicke encephalopathy (WE) is a clinical syn­drome characterized by the symptoms of mental status changes, ophthalmoplegia, unsteady gait and cerebellar dysfunctions that result from thiamine deficiency [1]. It is associated with significant morbidity and mortality, and, early diagnosis and prompt initiation of thiamine treatment is the critical point for better clinical outcomes [1]. However, the disease is still greatly underdiagnosed in both adults and children [1]. Herein, a rare patient of WE presenting with callosal lesion will be presented. Based on the dramatic recovery of the patient with efficient dosage of intravenous (IV) thiamine treatment, the importance of timely diagnosis and proper diagnosis will be discussed.

Case Report▴Top 

A 61-year-old man, with a history of 40 years of alcohol abuse, presented with gait impairment, ataxia and progressive amnesia which was recognized over the last 3 months. Progressive cognitive decline, sleep altera­tions, visual and tactile hallucinations (complaining of stinging and living in the patient’s skin) insects and dysarthria were also described during the evolution of the symptomatology which was remarkably recognized during the last 1 month. His condition had worsened significantly during this period, such that he had fall attacks several times due to prominent ataxia and he could not walk without support over the last 3 weeks. Of note, at admission to a health clinic 1 month ago with these symptoms, oral vitamin B-complex supplement (including 10 mg thiamine) 1 × 1 was initiated by a general practitioner due to chronic alcohol usage which had not given any benefit. At admission to our clinic, the patient was orientated and cooperative. However, severe dysarthria was recognized. Besides, content and speed of the speech were diminished. He was uninterested in the interview and his emotional responses were weakened that was compatible with apathetic state. The patient could move his eyes in all directions; however, slowness of the movements was recognized (compatible with saccadic dysfunction). Motor and sensory evaluations were within normal limits, whereas deep tendon reflexes were found to be hypoactive. On the other hand, cerebellar examinations revealed severe truncal ataxia. He could not walk in a straight line. Moreover, his gait was broad-based and significant walking unbalance was present, such that he had even survived the danger of falling several times during the neurological examination. Laboratory examinations including hemogram, biochemistry, thyroid functions and folic acid were normal. B12 level was mildly reduced (150 ng/L (normal range: 180 - 900)). Standardized mini-mental test (SMMT) score was evaluated as 15 points. Cranial magnetic resonance imaging (MRI) showed T2 hyperintense lesions in the splenium and genu corpus callosum, and mamillar body. A slight hyperintensity in the periaqueductal region was also recognized (Fig. 1). Besides, the electroneuromyography study disclosed moderate sensorial axonal polyneu­ropathy. Taking into account the history of alcohol abuse, the clinical and MRI findings, and the presence of peripheral neuropathy, WE was considered and high dosage IV thiamine treatment was initiated (3 × 500 mg IV thiamine in the first 5 days, 1 × 500 mg in the following 5 days and 100 mg thiamine as maintenance therapy). On evaluation 3 weeks later, a dramatic recovery was achieved. The dysarthric speech was nearly totally recovered and a significant improvement in gait disturbance was provided. He could easily walk without support and perform walking in a straight line. Besides, cognitive symptoms improved significantly. Repeated SMMT examination score was 23 points.

Figure 1.
Click for large image
Figure 1. Cranial magnetic resonance image shows T2 hyperintense lesions in the genu and splenium of the corpus callosum (b, d), mamillar body (e). A slight hyperintensity in the periaqueductal region was also recognized (c). Diffusion-weighted imaging shows high signal in the splenial lesion of the corpus callosum (f) (arrows).
Discussion▴Top 

WE is acknowledged to preferentially injure specific brain regions: the dorsomedial thalamus, periaqueductal gray and mamillary bodies [2]. Bilateral symmetric hyperintensity alterations in the periphery of the third ventricle, periaqueductal area, mammillary bodies and midbrain tectal plate on T2-weighted MR images have been acknowledged as the characteristic neuroimaging findings of WE [3]. However, less typically, symmetrical signal hyperintensities in additional regions including the caudate nucleus, cranial nerve nuclei, red nuclei, corpus callosum, dentate nuclei and cerebellum have also been reported to be seen in conjunction with WE [4]. In our case, the prominent finding on cranial MRI was T2 hyperintensity in the corpus callosum which is rather an atypical region for WE. In a unique report by Lee et al, the authors remarked to the corpus callosum atrophy in patients with WE and the authors emphasized that the clinical relevance of the corpus callosum atrophy in WE needs to be elucidated in further studies [5]. On the other hand, corpus callosum degeneration has been observed in chronic alcoholics, even in the absence of malnutrition, and has been attributed to cortical and white matter atrophy [6, 7]. Remarkably, in a previous report by Augusto et al, a 52-year-old female patient presenting with hallucinations and cognitive impairment was also reported at whom MRI revealed T2 hyperintense lesions in the corpus callosum that was similar to the lesion in our patient [8]. However, the authors preferred to describe this patient as Marchiafava-Bignami disease, rather than WE. Besides, they have constituted the discussion mainly around symptomatic treatment (rather than thiamine therapy) and the clinical outcome of the patient was not mentioned in detail. Hence, I think that the clinical presentation of our index case may provide substantial perspectives to be kept in mind in the clinical grounds.

Another important point may be that oral vitamin B supplement was also initiated 1 month prior to admission to our clinic which had failed to provide a clinical benefit. However, parenteral thiamine therapy yielded a dramatic improvement in all the symptoms of the patient. Remarkably, the researchers specifically recommend that in clinical suspicion of WE, high dosage parenteral thiamine treatment should be initiated, whereas oral thiamine is inadequate for preventing permanent brain damage [9]. Taken together, I would like to re-emphasize the importance of appropriate dosage and administration route of thiamine in the treatment of WE for optimal clinical responses.

In conclusion, based on the presentation of our patient, first, we suggest that the awareness of WE among clinicians should be further increased. Second, we re-emphasize the importance of initiation of parenteral thiamine treatments in clinical suspicion of WE which may provide dramatic responses even in patients with atypical lesion sites as in our patient. Future reports including outcomes of a larger number of cases with distinct neuroimaging signs may provide a better understanding of the real clinical burden of the disease as well as unknown aspects of WE.

Acknowledgments

None to declare.

Financial Disclosure

None to declare.

Conflict of Interest

None to declare.

Informed Consent

Informed consent form has been obtained from the patient and his relatives.

Author Contributions

The author solely prepared and wrote this article.


References▴Top 
  1. Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442-455.
    doi
  2. Loh Y, Watson WD, Verma A, Krapiva P. Restricted diffusion of the splenium in acute Wernicke's encephalopathy. J Neuroimaging. 2005;15(4):373-375.
    doi pubmed
  3. Jung YC, Chanraud S, Sullivan EV. Neuroimaging of Wernicke's encephalopathy and Korsakoff's syndrome. Neuropsychol Rev. 2012;22(2):170-180.
    doi pubmed
  4. Zuccoli G, Pipitone N. Neuroimaging findings in acute Wernicke's encephalopathy: review of the literature. AJR Am J Roentgenol. 2009;192(2):501-508.
    doi pubmed
  5. Lee ST, Jung YM, Na DL, Park SH, Kim M. Corpus callosum atrophy in Wernicke's encephalopathy. J Neuroimaging. 2005;15(4):367-372.
    doi pubmed
  6. Hommer D, Momenan R, Rawlings R, Ragan P, Williams W, Rio D, Eckardt M. Decreased corpus callosum size among alcoholic women. Arch Neurol. 1996;53(4):359-363.
    doi pubmed
  7. Estruch R, Nicolas JM, Salamero M, Aragon C, Sacanella E, Fernandez-Sola J, Urbano-Marquez A. Atrophy of the corpus callosum in chronic alcoholism. J Neurol Sci. 1997;146(2):145-151.
    doi
  8. Augusto L, Figueiredo R, Costa H, Reis C, Silva ML. Marchiafava-Bignami disease as a cause of visual hallucinations. Braz J Psychiatry. 2015;37(1):82.
    doi pubmed
  9. Flynn A, Macaluso M, D'Empaire I, Troutman MM. Wernicke's encephalopathy: increasing clinician awareness of this serious, Enigmatic, Yet Treatable Disease. The Primary Care Companion For CNS Disorders. 2015;17.
    doi pubmed


This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Journal of Neurology Research is published by Elmer Press Inc.

 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Neurology Research, biannually, ISSN 1923-2845 (print), 1923-2853 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.neurores.org   editorial contact: editor@neurores.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.


Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.